Hanmi Pharm. Co., Ltd. (KRX:128940)

South Korea flag South Korea · Delayed Price · Currency is KRW
366,000
-28,000 (-7.11%)
Jun 26, 2026, 3:30 PM KST
24.07%
Market Cap 4.64T
Revenue (ttm) 1.55T
Net Income (ttm) 172.44B
Shares Out 12.68M
EPS (ttm) 13,587.63
PE Ratio 26.94
Forward PE 23.93
Dividend 1,250.00 (0.34%)
Ex-Dividend Date Mar 30, 2026
Volume 101,643
Average Volume 192,036
Open 396,500
Previous Close 394,000
Day's Range 358,500 - 399,000
52-Week Range 267,500 - 647,000
Beta 0.44
RSI 36.16
Earnings Date Jul 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha... [Read more]

Sector Healthcare
Founded 1973
Employees 2,400
Stock Exchange Korea Stock Exchange
Ticker Symbol 128940
Full Company Profile

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩606,429, which is an increase of 65.69% from the latest price.

Price Target
₩606,429
(65.69% upside)
Analyst Consensus: Buy
Stock Forecasts

News

There is no news available yet.